User Meeting 2016

Session

Concurrent Session 3: Radiotherapy I

25 Nov 2016, 11:00

National Centre for Synchrotron Science

Conveners

Concurrent Session 3: Radiotherapy I

• Jeffrey Crosbie (RMIT University)

281. Clinical synchrotron radiotherapy programs from a medical physicist point of view

Dr Jean-François Adam (Université Grenoble-Alpes & Centre Hospitalier Universitaire Grenoble-Alpes)

25/11/2016, 11:00

Radiotherapy

Oral

Therapeutic applications of synchrotron x-rays are becoming a reality. The first phase I/II clinical study of Synchrotron Stereotactic Radiation Therapy (SSRT), in place at the European Synchrotron Radiation Facility (ESRF) since 2012, consists of a dose escalation protocol to show the feasibility and safety of the technique. 13 patients have been treated using 80 keV high-flux quasi-parallel...

175. Differential response of Diffuse Intrinsic Pontine Glioma cell lines to microbeam versus conventional radiotherapy

Mr Lloyd Smyth (University of Melbourne, Epworth HealthCare)

25/11/2016, 11:30

Radiotherapy

Oral

Background: Diffuse Intrinsic Pontine Glioma (DIPG) is a devastating paediatric brainstem tumour with extremely poor prognosis and limited treatment options. Radiotherapy is the mainstay treatment but is limited to palliative use. Microbeam Radiotherapy (MRT) is a promising pre-clinical synchrotron radiotherapy modality which could improve the therapeutic ratio between normal tissue toxicity...

200. Breast cancer rotational radiotherapy with synchrotron radiation

Francesca Di Lillo (Dept. of Phys. "Ettore Pancini", University of Naples Federico II,Naples, Italy & INFN, Sez. Napoli, Italy)

25/11/2016, 11:45

Radiotherapy

Oral

In 2012, J. Boone proposed the external-beam kilovoltage radiotherapy of the breast cancer with a dedicated setup adopting an orthovoltage X-ray tube [1] rotating in full circles around the breast, with the woman in prone position. For comparison, conventional radiotherapy for breast cancer adopts a medical linac irradiating the breast with tangential beams, in supine position: the megavoltage...

224. Synchrotron MRT radiation induces DNA damage and inflammatory response in normal mouse tissues distant from the irradiated volume

Mrs Jessica Ventura (The Department of Obstetrics and Gynaecology, The Royal Women’s Hospital, Melbourne, VIC; Molecular Radiation Biology Laboratory, Peter MacCallum Cancer Centre, Melbourne, VIC)

25/11/2016, 12:00

Radiotherapy

Oral

Discovery of the radiation-induced bystander effect (RIBE) demonstrates that cell death and genomic instability are not restricted to cells that are directly exposed to ionising radiation. The RIBE refers to a situation where cells that have not been directly exposed to IR behave as though they have been exposed. This phenomenon presents real clinical consequences such as increased risk of...

277. Optimizing Microbeam Radiation Therapy with High-Z Nano-structured Ceramic Particles

Prof. Michael Lerch (University of Wollongong)

25/11/2016, 12:15

Radiotherapy

Oral

Microbeam radiation therapy (MRT) implements spatially-fractionated kilovoltage x-rays for deep-seated tumour treatment [1,2] to provide better normal tissue sparing [3]. However, tumour treatment with MRT can be further optimized with high-Z nanoparticles (NPs), which have been shown to enhance the dose delivered by conventional radiotherapies [4]. Tantalum pentoxide (Ta2O5) NPs are novel...